Detalles de la búsqueda
1.
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Eur J Neurol;
30(8): 2357-2364, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154406
2.
Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.
Neurol Sci;
44(1): 45-58, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36114980
3.
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Neurol Sci;
43(11): 6415-6423, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781765
4.
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Mult Scler;
27(14): 2240-2253, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821693
5.
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry;
91(12): 1297-1303, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33055141
6.
Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study.
Environ Res;
182: 109022, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883496
7.
Anti-inflammatory and cognitive effects of interferon-ß1a (IFNß1a) in a rat model of Alzheimer's disease.
J Neuroinflammation;
16(1): 44, 2019 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30777084
8.
The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.
Med Sci Monit;
23: 4230-4240, 2017 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28864818
9.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ß1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Mult Scler;
22(9): 1163-73, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26466947
10.
Natalizumab in the pediatric MS population: results of the Italian registry.
BMC Neurol;
15: 174, 2015 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26407848
11.
A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects.
J Neuroinflammation;
11: 30, 2014 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24524367
12.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Mult Scler;
20(6): 705-16, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24126064
13.
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis.
Neurol Sci;
35(5): 789-91, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24514917
14.
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Neurol Sci;
35(2): 307-16, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24374787
15.
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol;
271(1): 340-354, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715789
16.
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.
Neurotherapeutics;
21(3): e00338, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38413275
17.
Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.
Mult Scler J Exp Transl Clin;
9(1): 20552173221144229, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36776745
18.
REal-World effectIveNess of claDribine for patients with multiple sclerosis: a Sicilian multicentric experience (REWIND study).
Curr Neuropharmacol;
2023 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36946484
19.
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
J Neurol;
270(10): 4687-4696, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405689
20.
The molecular anatomy of human Hsp60 and its similarity with that of bacterial orthologs and acetylcholine receptor reveal a potential pathogenetic role of anti-chaperonin immunity in myasthenia gravis.
Cell Mol Neurobiol;
32(6): 943-7, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22258649